Selected publications
-
Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models
Langdon, S. P., Kay, C., Um, I. H., Muir, M., Sellar, G., Kan, J., Gourley, C. & Harrison, D. J., 10 Dec 2019, In : Scientific Reports. 9, 9 p., 18742.Research output: Contribution to journal ? Article
-
Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031
Sarr, A., Bré, J., Um, I. H., Chan, T. H., Mullen, P., Harrison, D. J. & Reynolds, P. A., 21 May 2019, In : Scientific Reports. 9, 13 p., 7643.Research output: Contribution to journal ? Article
-
Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models
Koussounadis, A., Langdon, S., Um, I. H., Kay, C., Francis, K., Harrison, D. J. & Smith, V. A., 10 Mar 2016, In : BMC Cancer. 16, 13 p., 205.Research output: Contribution to journal ? Article
-
Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models
Ward, C., Meehan, J., Mullen, P., Supuran, C., Dixon, J. M., Thomas, J. S., Winum, J-Y., Lambin, P., Dubois, L., Pavathaneni, N-K., Jarman, E. J., Renshaw, L., Um, I. H., Kay, C., Harrison, D. J., Kunkler, I. H. & Langdon, S. P., 2015, In : Oncotarget. 6, 28, p. 24865-24870 15 p.Research output: Contribution to journal ? Article
-
Multi-scale genomic, transcriptomic and proteomic analysis of colorectal cancer cell lines to identify novel biomarkers
Briffa, R., Um, I. H., Faratian, D., Zhou, Y., Turnbull, A. K., Langdon, S. P. & Harrison, D. J., 17 Dec 2015, In : PLoS One. 10, 12, 29 p., e0144708.Research output: Contribution to journal ? Article
-
Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system
Koussounadis, A., Langdon, S., Um, I. H., Harrison, D. J. & Smith, V. A., 8 Jun 2015, In : Scientific Reports. 5, 9 p., 10775.Research output: Contribution to journal ? Article
-
The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer
Huang, R., Langdon, S. P., Tse, M., Mullen, P., Um, I. H., Faratian, D. & Harrison, D. J., 14 Dec 2015, In : Oncotarget. 7, 4, p. 4695-4711 17 p.Research output: Contribution to journal ? Article
-
Characterisation of phosphorylated checkpoint kinase 1 as a poor prognostic biomarker in serous ovarian cancer
Francis, K. E., Mullen, P., Um, I., Kay, C., Harrison, D. J. & Langdon, S. P., Sep 2013, In : Journal of Pathology. 231, p. 46 1 p.Research output: Contribution to journal ? Abstract
-
The use of aromatase inhibitors in ovarian cancer and identification of responsive tumors: Aromatase inhibitors: Types, Mode of Action and Indications
Langdon, S., Faratian, D., Gourley, C., Harrison, D., Um, I. H. & Smyth, J., 2009, Aromatase inhibitors: Types, Mode of Action and Indications. Nova Science Pub Incorporated, p. 163-174 12 p. (Cancer Etiology, Diagnosis and Treatment Series).Research output: Chapter in Book/Report/Conference proceeding ? Chapter